# Minimal Change Disease

Adult minimal change disease requires kidney-biopsy confirmation, exclusion of secondary drivers, prompt management of nephrotic complications, and a prolonged glucocorticoid course. Relapse pattern, steroid toxicity, and kidney function determine whether cyclophosphamide, calcineurin inhibition, or other steroid-sparing therapy is appropriate.

**Clinical question:** How should physicians diagnose, treat, and monitor adult minimal change disease presenting with nephrotic syndrome?

Updated: 2026-08-24T17:49:42.003171+00:00

## What matters in practice
- In adults with new nephrotic syndrome, obtain a kidney biopsy before assigning minimal change disease; presentation overlaps with other glomerular diseases, while biopsy directs treatment.[17]
- Minimal change disease shows little or no abnormality by light microscopy, negative immunofluorescence for immune-complex deposition, and diffuse podocyte foot-process effacement on electron microscopy.[3][19]
- For an initial adult episode, prednisone or prednisolone 1 mg/kg daily (maximum 80 mg) or 2 mg/kg every other day (maximum 120 mg) is recommended; maintain high-dose treatment for at least 4 weeks after complete remission or up to 16 weeks if remission has not occurred.[15]
- Adults have meaningful acute kidney injury risk: hematuria occurs in 20% to 30% and AKI in 20% to 25%; older age, hypertension, arteriosclerosis on biopsy, and high-grade proteinuria increase concern.[17]
- For frequently relapsing or steroid-dependent disease, cyclophosphamide, calcineurin inhibitors, and rituximab are steroid-sparing options; drug choice should account for reproductive risk, nephrotoxicity, cumulative steroid exposure, and relapse history.[16][17]

## Confirm MCD and identify competing nephrotic lesions

Do not treat adult nephrotic syndrome as presumed MCD without histology.

Quantify proteinuria and assess urine sediment, serum albumin, creatinine, and blood pressure at presentation. A nephrotic pattern usually has proteinuria greater than 3.5 g per 24 hours with relatively inactive urine sediment; red-cell casts or dysmorphic erythrocytes instead favor a nephritic glomerular process requiring a different diagnostic pathway.[20]

Perform kidney biopsy in adults with suspected MCD because clinical nephrotic syndrome cannot reliably distinguish MCD from focal segmental glomerulosclerosis (FSGS), membranous nephropathy, diabetic kidney disease, amyloidosis, or other causes. Histologic MCD requires correlation across light microscopy, immunofluorescence, and electron microscopy: minimal light-microscopic change, absent immune-complex staining, and diffuse foot-process effacement without electron-dense deposits.[3][17][19]

If biopsy identifies segmental sclerosis, reassess for primary versus secondary FSGS rather than applying an MCD regimen automatically. Podocytopathies can show MCD or FSGS lesions, and treatment response with resolution of proteinuria is prognostically important; persistent proteinuria is associated with poor renal prognosis in primary podocytopathies.[5]
- Review medication exposure and systemic context before labeling disease idiopathic; reported secondary associations include NSAIDs, lithium, and antibiotics.[21]
- In pregnancy with persistent or severe nephrotic-range proteinuria, particularly with normal liver enzymes and platelets or only mild hypertension, broaden beyond preeclampsia and use kidney biopsy when pathology will change management.[21]

*Biopsy-centered distinction of nephrotic and nephritic patterns [3][19][20]*

| Finding | Interpretation | Next action |
| --- | --- | --- |
| Proteinuria >3.5 g/24 h with few cells or casts | Nephrotic-pattern glomerular disease; MCD remains one of several possibilities.[20] | Proceed to etiologic evaluation and, in adults with suspected MCD, kidney biopsy.[17] |
| Red-cell casts or dysmorphic red cells | Nephritic-pattern glomerular injury rather than uncomplicated MCD.[20] | Evaluate for inflammatory glomerulonephritis, including infection-related GN, IgA nephropathy, lupus nephritis, anti-GBM disease, and vasculitis.[20] |
| Minimal light-microscopic alteration, negative immunofluorescence, diffuse foot-process effacement | Pathologic pattern supporting MCD.[3][19] | Assess for secondary drivers and begin MCD-directed management.[21] |
| Segmental glomerular sclerosis | FSGS lesion rather than isolated MCD pattern.[5][19] | Classify the FSGS process and avoid assuming steroid-responsive MCD.[5] |

## Address kidney dysfunction and nephrotic complications while pathology is finalized

Supportive management should run in parallel with diagnostic confirmation.

Assess for AKI at every initial and relapse presentation with serial serum creatinine, volume assessment, blood pressure, and urine output. AKI occurs in approximately 20% to 25% of adults with MCD; risk is greater with older age, hypertension, arteriosclerosis on biopsy, and high-grade proteinuria. Acute tubular necrosis has been reported in up to 60% of affected adults, and recovery may occasionally be incomplete.[17]

Use diuretics for symptomatic edema and reassess volume status and kidney function during decongestion. Renin-angiotensin system antagonists can reduce proteinuria and slow fibrosis progression in podocytopathies; adjunctive management may include statins, infection prophylaxis, and anticoagulation when clinically indicated by the nephrotic state and patient-specific risk.[5]

Before high-dose glucocorticoids, document weight, blood pressure, and examination findings for infection and systemic disease; serial weight is useful for tracking edema response.[19]
- Escalate urgency for rapidly rising creatinine, oliguria, severe hypertension, active urine sediment, or features suggesting an alternative inflammatory glomerulonephritis rather than uncomplicated MCD.[17][20]
- Follow proteinuria, serum albumin, creatinine, weight, and blood pressure to distinguish remission, persistent nephrosis, treatment toxicity, and AKI.[17][19]

*Initial monitoring priorities in adult MCD [17][19]*

| Domain | Measure | Decision relevance |
| --- | --- | --- |
| Kidney function | Serial serum creatinine and urine output.[17] | Detect AKI, which occurs in 20% to 25% of adults with MCD.[17] |
| Edema and hemodynamics | Weight, blood pressure, and clinical volume assessment.[19] | Guide diuretic response and identify hemodynamic deterioration.[19] |
| Disease activity | Proteinuria and serum albumin.[5][19] | Track nephrotic activity and response to immunosuppression.[5] |
| Treatment safety | Infection assessment before corticosteroids and at follow-up.[19] | Identify complications that may alter immunosuppressive treatment.[19] |

## Use glucocorticoids for biopsy-confirmed adult MCD

Dose, duration, and taper should be explicit from the first prescription.

For the initial adult episode of MCD, use prednisone or prednisolone 1 mg/kg as a single daily dose (maximum 80 mg) or 2 mg/kg as a single alternate-day dose (maximum 120 mg).[15] The KDIGO 2021 glomerular-disease guideline includes a dedicated adult MCD chapter, and the subsequent KDIGO update judged that chapter still current because no new evidence had been identified to revise it.[12][14]

If complete remission occurs, continue the tolerated high dose for a minimum of 4 weeks. If complete remission has not occurred, high-dose therapy may be continued for up to 16 weeks; do not declare early treatment failure solely because adult remission is slower than pediatric remission.[15]

After remission, taper glucocorticoids slowly, with total taper duration of up to 6 months after remission. During the taper, follow proteinuria, creatinine, blood pressure, weight, and adverse effects of prolonged corticosteroid exposure.[15][19]
- Use a steroid-sparing induction strategy when high-dose glucocorticoids pose unacceptable toxicity or are contraindicated; calcineurin inhibitors and enteric-coated mycophenolate sodium with or without reduced-dose prednisolone have achieved remission in studies, with some reduction in steroid-associated adverse effects.[16]
- Interpret apparent glucocorticoid resistance cautiously: revisit biopsy adequacy, pathology, medication-associated disease, and alternative podocytopathy before escalating immunosuppression.[3][5][17]

*Initial glucocorticoid regimen for adult MCD [15]*

| Treatment phase | Regimen | Timing rule |
| --- | --- | --- |
| Induction | Prednisone/prednisolone 1 mg/kg daily, maximum 80 mg; or 2 mg/kg every other day, maximum 120 mg.[15] | Start after diagnostic assessment and use as initial treatment for adult MCD.[15] |
| After complete remission | Continue tolerated high-dose treatment.[15] | Maintain for at least 4 weeks after complete remission.[15] |
| No complete remission | Continue high-dose treatment if tolerated.[15] | Maximum initial high-dose duration is 16 weeks.[15] |
| Taper | Reduce slowly after remission.[15] | Complete taper over up to 6 months after remission.[15] |

## Match relapse management to steroid dependence and treatment toxicity

Reinduce remission, then select a strategy that minimizes cumulative toxicity.

For frequently relapsing or steroid-dependent adult MCD, cyclophosphamide has extensive clinical experience as a steroid-sparing option. After remission is regained with prednisone, oral cyclophosphamide may be given at 1 to 2 mg/kg daily for 8 to 12 weeks.[17] Discuss infertility risk and cumulative alkylator exposure before prescribing, particularly in patients with future reproductive plans.

During cyclophosphamide treatment, obtain weekly white blood cell counts and adjust or interrupt dosing to prevent leukopenia, defined in this approach as white blood cell count below 3,000/mm3 or neutrophil count below 1,500/mm3.[17]

Calcineurin inhibitors are another remission-induction and steroid-sparing approach, but nephrotoxicity is a key tradeoff. Evidence synthesis supports calcineurin inhibitors and enteric-coated mycophenolate sodium, with or without reduced-dose prednisolone, as potentially effective for remission in adults; optimal agent, dose, duration, and management of relapsing or prednisolone-resistant disease remain uncertain.[16]

Rituximab has been used in adults with steroid-dependent MCD and is recognized among treatment options for refractory disease, but randomized trial data in adults were still awaited in the cited systematic review. Use it as a specialist-directed option when relapse burden or toxicity makes conventional approaches unsuitable.[16][17]
- Choose cyclophosphamide when a finite 8- to 12-week course and intensive hematologic monitoring are acceptable.[17]
- Choose a calcineurin inhibitor when avoiding cumulative cyclophosphamide toxicity is prioritized, while monitoring for nephrotoxicity.[16][24]
- Consider rituximab for steroid-dependent or refractory disease in consultation with nephrology, recognizing the limited randomized adult evidence base.[16][17]

*Steroid-sparing options for relapsing or steroid-dependent adult MCD [16][17]*

| Option | When considered | Regimen or monitoring | Key tradeoff |
| --- | --- | --- | --- |
| Cyclophosphamide | Frequently relapsing or steroid-dependent disease after prednisone-induced remission.[17] | 1-2 mg/kg orally daily for 8-12 weeks; check white blood cell count weekly and avoid WBC <3,000/mm3 or neutrophils <1,500/mm3.[17] | Infertility and leukopenia risk require pre-treatment counseling and active dose adjustment.[17] |
| Calcineurin inhibitor | Steroid-sparing induction or relapsing disease when corticosteroid toxicity is a concern.[16] | Specific adult dose and duration are not established in the cited evidence.[16] | Nephrotoxicity is an important limitation.[24] |
| Enteric-coated mycophenolate sodium | Potential reduced-steroid strategy in adult MCD.[16] | May be used with or without reduced-dose prednisolone; optimal regimen remains undetermined.[16] | Evidence for relapsing and prednisolone-resistant disease remains limited.[16] |
| Rituximab | Steroid-dependent or refractory disease managed with nephrology input.[16][17] | Adult randomized efficacy data were awaited in the cited review.[16] | Use reflects limited trial certainty rather than a defined standard dose in these sources.[16] |

## Monitor remission, recurrence, and renal trajectory

Follow disease activity and treatment injury rather than proteinuria alone.

At each follow-up, measure proteinuria, serum creatinine, blood pressure, weight, and edema burden. Resolution of proteinuria is clinically meaningful in primary podocytopathies, whereas nonresolution is associated with poor renal prognosis.[5]

Reconsider the diagnosis when proteinuria persists despite an adequate glucocorticoid exposure, kidney function deteriorates, or urine sediment becomes active. A biopsy pattern of FSGS, immune deposits, or a nephritic sediment should redirect evaluation and treatment away from uncomplicated MCD.[3][5][19][20]

For patients receiving prolonged corticosteroids, continue surveillance for infection and document weight and blood pressure. For cyclophosphamide, weekly blood counts are required during therapy; for calcineurin inhibitor-based treatment, monitor kidney function because nephrotoxicity is a recognized limitation.[17][19][24]
- Use relapse frequency, cumulative steroid toxicity, kidney function, and patient reproductive priorities to revisit steroid-sparing strategy at each recurrence.[16][17]
- Maintain renin-angiotensin system antagonism when tolerated for antiproteinuric and antifibrotic benefit in podocytopathies.[5]

*Triggers to reassess the working diagnosis or treatment plan [3][5][17][20]*

| Trigger | Concern | Action |
| --- | --- | --- |
| Persistent nephrotic proteinuria after planned induction window | MCD may be treatment-resistant or pathology may represent another podocytopathy or glomerular disease.[5][15] | Review biopsy findings and secondary causes; involve nephrology before escalating immunosuppression.[17] |
| Rising creatinine or oliguria | MCD-associated AKI, hemodynamic injury, or an alternative renal process.[17] | Assess volume status, repeat kidney-function testing, and reassess urine sediment.[17][20] |
| Red-cell casts or dysmorphic erythrocytes | Nephritic glomerular disease rather than inactive-sediment MCD.[20] | Evaluate for inflammatory glomerulonephritis and revise diagnostic pathway.[20] |
| Relapse during taper or repeated recurrence | Steroid dependence or frequent relapsing disease.[16][17] | Reinduce remission and select a steroid-sparing strategy based on toxicity and monitoring feasibility.[17] |

## References
1. Focal Segmental Glomerulosclerosis — www.nejm.org — https://www.nejm.org/doi/pdf/10.1056/NEJMra1106556
2. Structured illumination microscopy and automatized image ... — www.nature.com — https://www.nature.com/articles/s41598-017-11553-x
3. Autoantibodies Targeting Vinculin Reveal Novel Insight into the Mechanisms of Autoimmune Podocytopathies — spj.science.org — https://spj.science.org/doi/10.34133/research.0722
4. Glomerular Disease Pathophysiology and Clinical Outcomes | Nephrology and Urology | Clinical Sciences | Health sciences | Topics | Nature Index — www.nature.com — https://www.nature.com/nature-index/topics/l4/glomerular-disease-pathophysiology-and-clinical-outcomes
5. Podocytopathies | Nature Reviews Disease Primers — www.nature.com — https://www.nature.com/articles/s41572-020-0196-7
6. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0085253821005536
7. KDOQI US Commentary on the KDIGO 2025 Clinical ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0272638625011473
8. A Case Report of Giant Congenital Melanocytic Nevus ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/ccr3.70794
9. The Impact of Histologic Variants on FSGS Outcomes — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1155/2014/913690
10. A membranous nephropathy variant mimicking minimal ... — pathsocjournals.onlinelibrary.wiley.com — https://pathsocjournals.onlinelibrary.wiley.com/doi/full/10.1002/2056-4538.70062
11. Advanced therapeutics in focal and segmental ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/nep.13463
12. KDIGO 2021 Clinical Practice Guideline for the ... — www.kidney-international.org — https://www.kidney-international.org/article/S0085-2538(21)00562-7/fulltext
13. CARI Guidelines Commentary on the KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12439324
14. KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) — www.kidney-international.org — https://www.kidney-international.org/article/S0085-2538(25)00279-0/fulltext
15. The Evidence-Based Approach to Adult-Onset Idiopathic Nephrotic Syndrome — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4585181
16. Interventions for minimal change disease in adults with nephrotic syndrome — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8887628
17. Management of Adult Minimal Change Disease - PMC - NIH — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6556731
18. Minimal Change Disease - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK560639
19. Nephrotic Syndrome - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK470444
20. Chronic Kidney Disease - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK535404
21. American Society of Nephrology | Kidney Week - Abstract Details (2025) — www.asn-online.org — https://www.asn-online.org/education/kidneyweek/2025/program-abstract.aspx?controlId=4353085
22. American Society of Nephrology | Kidney Week - Abstract Details (2019) — www.asn-online.org — https://www.asn-online.org/education/kidneyweek/2019/program-abstract.aspx?controlId=3235031
23. NEPHROTIC SYNDROME: MINIMAL CHANGE DISEASE — applications.emro.who.int — https://applications.emro.who.int/imemrf/J_Ayub_Med_Coll_Abbotabad_Pak/J_Ayub_Med_Coll_Abbotabad_Pak_2001_13_4_35_40.pdf
24. [PDF] ACTH for Frequently Relapsing and Steroid Dependent Nephrotic ... — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/95/NCT02132195/Prot_SAP_000.pdf

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.